Rare genetic disorders impact 10% of people worldwide. Despite identifying over 8,000 such conditions, most patients remain undiagnosed or untreated, facing lifelong challenges and limited treatment options. Yet, there’s hope: gene therapy holds the potential not only to treat but possibly cure these disorders by correcting the underlying genetic errors.
Our project is dedicated to uncovering the genetic changes that lead to rare genetic disorders, particularly in children. By exploring the UK Biobank database, which houses extensive genetic data and clinical information on patients with a range of conditions, including blood disorders, congenital heart defects (CHD), orofacial clefting (OFC), and other rare diseases, our goal is to unearth new genetic causes of these disorders, laying the groundwork to transform our understanding of their impact.
The scientific rationale behind our work is clear: by identifying the specific genetic mutations responsible for these conditions, we can open doors to developing precise treatments. This means moving beyond symptom management to addressing the root cause of conditions like CHD and OFC. Our research will fill critical gaps in our knowledge and serve as a beacon of hope for affected families.
While we focus on understanding rare genetic diseases in children, many of these conditions are diagnosed in adulthood. By studying adult samples, we can better understand these diseases in children. Additionally, since many of these disorders are inherited from parents, studying adults can help us identify the genetic factors in the parents of affected children. This approach will provide valuable insights into these inherited blood disorders and improve our ability to diagnose and treat them in children.
This project will initially span three years, during which we will analyze known and novel genetic variations. By embracing cutting-edge computational techniques and the rich data available through the UK Biobank, we are uniquely positioned to make significant advancements.
The impact of our research on public health cannot be overstated. For millions of children living with rare genetic disorders, our findings could mean the difference between a life constrained by illness and one with the potential for cure and improvement. Through our commitment to sharing our discoveries, we aim to catalyze innovation in treatment and care for rare diseases, offering new avenues for diagnosis, targeted therapies, and even curative approaches through gene therapy.